Article successfully added.

CyFlow™ CD11a Low Endotoxin

CyFlow™ CD11a Low Endotoxin
Alternative Name: LFA-1
Antibody: Yes
Antigen: CD11a
Application: Flow cytometry, Functional assays, Immunoprecipitation
Clonality: monoclonal
Clone: MEM-83
Field of Interest: Immunophenotyping
Format/Fluorochrome: Low Endotoxin
Isotype: IgG1
Regulatory Status: RUO
Source Species: Mouse
Target Species: Human
Product number: CG358525

For Research Use Only

$153.07 CAD*

Price excludes any applicable taxes plus shipping costs

Concentration Unit mg/mL Concentration 1 Quantity 0.1 mg Volume 0.1 mL... more
CyFlow™ CD11a Low Endotoxin
Concentration Unitmg/mL
Concentration1
Quantity0.1 mg
Volume0.1 mL
ImmunogenHuman peripheral blood lymphocytes
Background InformationCD11a (LFA-1 α) together with CD18 constitute leukocyte function-associated antigen 1 (LFA-1), the αLβ2 integrin. CD11a is implicated in activation of LFA-1 complex. LFA-1 is expressed on the plasma membrane of leukocytes in a low-affinity conformation. Cell stimulation by chemokines or other signals leads to induction the high-affinity conformation, which supports tight binding of LFA-1 to its ligands, the intercellular adhesion molecules ICAM-1, -2, -3. LFA-1 is thus involved in interaction of various immune cells and in their tissue-specific settlement, but participates also in control of cell differentiation and proliferation and of T-cell effector functions. Blocking of LFA-1 function by specific antibodies or small molecules has become an important therapeutic approach in treatment of multiple inflammatory diseases. For example, humanized anti-LFA-1 antibody Efalizumab (Raptiva) is being used to interfere with T cell migration to sites of inflammation; binding of cholesterol-lowering drug simvastatin to CD11a allosteric site leads to immunomodulation and increase in lymphocytic cholinergic activity.
Storage BufferThe reagent is provided in azide-free phosphate buffered saline (PBS) solution, pH ≈7.4; 0.2 µm filter sterilized. Endotoxin level is less than 0.01 EU/µg of the protein, as determined by the LAL test.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Knapp W, Dorken B, Gilks W, Rieber EP, Schmidt RE, Stein H, von dem Borne AEGK (Eds): Leucocyte Typing IV. Oxford University Press, Oxford. 1989; 1‑1820. < NLM ID: 8914679 > | Landis RC, Bennett RI, Hogg N: A novel LFA‑1 activation epitope maps to the I domain. J Cell Biol. 1993 Mar; 120(6):1519‑27. < PMID: 7680657 > | Landis RC, McDowall A, Holness CL, Littler AJ, Simmons DL, Hogg N: Involvement of the "I" domain of LFA‑1 in selective binding to ligands ICAM‑1 and ICAM‑3. J Cell Biol. 1994 Jul; 126(2):529‑37. < PMID: 7518468 > | Sarantos MR, Raychaudhuri S, Lum AF, Staunton DE, Simon SI: Leukocyte function‑associated antigen 1‑mediated adhesion stability is dynamically regulated through affinity and valency during bond formation with intercellular adhesion molecule‑1. J Biol Chem. 2005 Aug 5; 280(31):28290‑8. < PMID: 15955822 > | Giblin PA, Lemieux RM: LFA‑1 as a key regulator of immune function: approaches toward the development of LFA‑1‑based therapeutics. Curr Pharm Des. 2006; 12(22):2771‑95. < PMID: 16918410 > | Kellersch B, Kolanus W: Membrane‑proximal signaling events in beta‑2 integrin activation. Results Probl Cell Differ. 2006; 43:245‑57. < PMID: 17068975 > | Fujii T, Takada-Takatori Y, Kawashima K: Roles played by lymphocyte function‑associated antigen‑1 in the regulation of lymphocytic cholinergic activity. Life Sci. 2007 May 30; 80(24‑25):2320‑4. < PMID: 17289088 >